Castration Resistant, Taxane Naïve Metastatic Prostate Cancer: Current Clinical Approaches and Future Directions

Keyphrases

• Nave 100%
• Taxanes 100%
• Clinical Approach 100%
• Castration-resistant 100%
• Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 100%
• Docetaxel 100%
• Experimental Therapeutics 66%
• Functional Status 33%
• Signaling Axis 33%
• Patient Demographics 33%
• Immune System 33%
• Randomized Trial 33%
• Comorbidity 33%
• Disease Progression 33%
• Treatment Options 33%
• Metastatic Disease 33%
• Conventional Chemotherapy 33%
• Prostate-specific Antigen 33%
• Natural History 33%
• Therapeutic Goals 33%
• Current Management 33%
• Androgen Deprivation Therapy 33%
• Palliation 33%
• Androgen Signaling 33%
• Multiple Agents 33%
• Therapy Choice 33%
• Cytotoxic Agents 33%
• Novel Cytotoxics 33%
• Chemotherapy Duration 33%
• Anti-angiogenic Strategies 33%
• Anti-apoptotic Pathways 33%
• Taxane-based Chemotherapy 33%

Medicine and Dentistry

• Chemotherapy 100%
• Prostate Cancer 100%
• Medical Decision Making 100%
• Docetaxel 100%
• Experimental Therapy 66%
• Symptomatic Treatment 33%
• Immunity 33%
• Functional Status 33%
• Disease Exacerbation 33%
• Metastatic Carcinoma 33%
• Prostate Specific Antigen 33%
• Patient Population 33%
• Immune System 33%
• Androgen Receptor 33%
• Cytotoxic Agent 33%
• Antiangiogenic Therapy 33%
• Antiapoptotic 33%
• Androgen 33%
• Comorbidity 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Prostate Cancer 100%
• Docetaxel 100%
• Taxane 100%
• Antiangiogenic 33%
• Antiapoptotic 33%
• Metastasis 33%
• Disease Exacerbation 33%
• Prostate Specific Antigen 33%
• Functional Status 33%
• Androgen Receptor 33%
• Cytotoxic Agent 33%
• Androgen 33%
• Comorbidity 33%